Condition category
Cancer
Date applied
24/04/2016
Date assigned
09/05/2016
Last edited
25/05/2016
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Irreversible Electroporation (IRE) is a novel method for focused treatment of liver tumors. IRE is a soft tissue ablation technique (that is, a technique used to remove soft body tissues, including tumors) using ultra-short but strong electrical fields to create permanent and hence lethal nanopores (tiny holes) in the cell membrane resulting in cell death. IRE ablation requires the placement of two or more applicator electrodes between which the electrical fields are applied. In order to achieve successful ablation, parallel needle placement at a pre-defined distance is required. Needles are placed under image guidance using ultrasound or computer tomography as imaging methods. Since these methods display one image plane at a time, the realization of multiple parallel needle placements can be challenging. Several attempts may be required to achieve the required geometrical configuration of the needle with respect to other needles and as well as in relation to the anatomical target. Navigation technology for interventional radiology supports IRE treatments by providing comprehensive planning of needle configurations using 3D image data and by supporting needle placement through guidance functionality. This study aims to investigate the potential benefits of CT-navigated stereotactic IRE needle placement compared to non-navigated conventional IRE.

Who can participate?
Adult patients (aged at least 18) about to be treated with IRE for liver tumors.

What does the study involve?
Participants are split into two groups. Those in group 1 undergo the CT-navigated stereotactic IRE. Those in group 2 are treated by conventional IRE using manual needle placement. The time taken for accurate IRE needle placement for all patients is assessed, along with overall time of procedure and the radiation dose required for the IRE session.

What are the possible benefits and risks of participating?
Potential benefits for patients undergoing stereotactic IRE might be faster intervention times. No additional risks or side effects are expected .

Where is the study run from?
Department of Radiology at the University Hospital Regensburg (Germany)

Who is the main contact?
Dr Lukas Beyer

Trial website

Contact information

Type

Scientific

Primary contact

Dr Lukas Beyer

ORCID ID

Contact details

Franz-Josef-Strauß-Allee 11
Regensburg
93053
Germany

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

1.0

Study information

Scientific title

Pilot study comparing needle placement for Irreversible Electroporation (IRE) using CT navigation versus conventional CT-guidance: a non-randomized prospective two-arm study

Acronym

Study hypothesis

CT-navigation allows for faster placement of IRE needle applicators with a reduced number of pre-placements and control scans.

Ethics approval

University Hospital Regensburg (02/2015).

Study design

Non-randomized prospective two-arm study.

Primary study design

Interventional

Secondary study design

Non randomised study

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

See additional files

Condition

Liver cancer

Intervention

Irreversible Electroporation (IRE) is a novel method for focused treatment of liver tumors. IRE is a soft tissue ablation technique using ultra short but strong electrical fields to create permanent and hence lethal nanopores in the cell membrane, to disrupt the cellular homeostasis. The resulting cell death results from apoptosis and not necrosis as in all other thermal or radiation based ablation techniques. IRE is used for non-resectable liver tumors in the vicinity of vessels (due to the its selectivity for tumor tissue while preserving vessel structures).

IRE ablation requires the placement of two or more applicator electrodes between which the electrical fields are applied. In order to achieve successful ablation, parallel needle placement at a pre-defined distance is required. Needles are placed under image guidance using ultrasound or computer tomography as imaging methods. As these methods are displaying one image plane at a time, the realization of multiple needle placements can be challenging and can require several attempts until the required geometrical configuration of the needle with respect to other needles and also to the anatomical target is achieved.
Navigation technology for interventional radiology supports IRE treatments by providing comprehensive planning of needle configurations using 3D image data and by supporting needle placement through guidance functionality.

This study aims to investigate the potential benefits of CT-navigated IRE needle placement compared to conventional non-navigated techniques.

Intervention type

Device

Phase

Drug names

Primary outcome measures

Time required for the placement of IRE needles (measured from the time of the first CT scan to the start of the ablation).

Secondary outcome measures

1. Accuracy of IRE needle placement compared to a patient-specific ablation strategy (accuracy is measured as distance to the target point, distance between needles, angles between needles)
2. Overall procedure time
3. Number of lesions treated per patient
4. Number of needle replacements
5. Number of control scans
6. Radiation dose

Overall trial start date

01/07/2015

Overall trial end date

01/03/2016

Reason abandoned

Eligibility

Participant inclusion criteria

1. Patients must be scheduled for CT guided percutaneous IRE in the liver
2. Written informed consent
3. Male patients and non-pregnant, non-lactating females aged ≥18 years of age (negative serum/urine pregnancy test result at screening)

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

20

Participant exclusion criteria

1. Any condition which, in the judgment of the clinical investigator or his designee, might increase the risk to the subject or decrease the chance of obtaining satisfactory data to achieve the objectives of the study
2. A mental condition rendering the patient unable to provide informed consent
3. Patients with hereditary haematological / coagulation disorders unrelated to their liver disease.
4. Patients who are currently (within the last 30 days prior to surgery) participating in another clinical trial with any investigational drug or device
5. Patients undergoing liver surgery for the purpose of receiving a liver transplant or for liver trauma
6. Patients with established renal insufficiency (Creatinine >2.5 mg/dl), or a condition requiring hemodialysis

Recruitment start date

01/07/2015

Recruitment end date

31/01/2016

Locations

Countries of recruitment

Germany

Trial participating centre

University Hospital Regensburg
93053
Germany

Sponsor information

Organisation

University Hospital Regensburg

Sponsor details

Franz-Josef-Strauß-Allee 11
Regensburg
930533
Germany
015151121489
lukas@lukasbeyer.com

Sponsor type

Hospital/treatment centre

Website

Funders

Funder type

Hospital/treatment centre

Funder name

Universitätsklinikum Regensburg

Alternative name(s)

University Hospital Regensburg, UKR

Funding Body Type

government organisation

Funding Body Subtype

government non-federal

Location

Germany

Results and Publications

Publication and dissemination plan

Intention to publish date

01/03/2017

Participant level data

To be made available at a later date

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes

25/05/2016: Uploaded participant information sheet